Oclaiz (CAM2029) PDUFA Date (Camurus)
FDA PDUFA decision date for Oclaiz (CAM2029) is June 10, 2026. Developed by Camurus. Indication: Acromegaly — long-acting octreotide subcutaneous depot. Current status: Verifying.
Indication
Acromegaly — long-acting octreotide subcutaneous depot
Notes
Long-acting subcutaneous octreotide depot for acromegaly.
Regulatory details
- Company: Camurus
- Therapeutic area: Rare Disease / Endocrine
- Application type: NDA
- Review type: Standard
- PDUFA date: 2026-06-10
- Outcome: Pending